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one agent were less likely to persist than those initiated on a prostaglandin analog. 
Those initiated on parasympathomimetic, beta blocking agent or on more than one 
agent were less likely to be compliant. Carbonic anhydrase inhibitors users were more 
likely to be compliant. CONCLUSIONS: Among the new antiglaucoma treatment 
users, 24% adhered to their treatment. The initial drug inﬂuences the likelihood of 
both persistence and compliance.
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OBJECTIVES: To assess French patient’s characteristics and ophthalmologists man-
agement of glaucoma in 2009. METHODS: An internet cross-sectional one-day 
 multicentre study led in France aimed at describing management of glaucoma (G)/
ocular hypertension (OHT)—deﬁned by an intraocular pressure q21 mm Hg, and also 
at assessing satisfaction and compliance. RESULTS: Two hundred eighty-eight oph-
thalmologists included 963 patients, 43.2% were male. Open-angle-glaucoma (OAG) 
in 71.7% and OHT in 24.3% of cases were motives for consultation. For OAG and 
OHT mean disease duration was respectively 9.2 o 7.7 years and 5.0 o 5.3 years. 
Mean age was respectively 58.2 o 12.9 and 54.7 o 12.5, mean IOP 17.5 o 4.9 and 
19.1 o 4.2 mm Hg. Average treatment duration was 8.0 o 7.1 years, mean number of 
treatment changes 2.0 o 2.3. Previous treatment consisted in laser in 16.2% of cases, 
surgery 10.5%, laser plus surgery 4.6%. Medical treatment was administered in 
94.0% of OAG patients and in 74.9% of OHT patients. Monotherapy was 50.7% 
of medical treatment, ﬁxed association 16.4%, non-ﬁxed associations 32.9%. In 
monotherapy group, beta-blockers (BB) part was 31.7%, prostaglandins (PG) 50.7% 
and carbonic anhydrase inhibitors CAI 5.9%. In ﬁxed association group BBPG were 
used in 72.5% of cases, BBCAI in 20.3% and BB ADR 6.5%. Whatever is the 
medical treatment, changes are secondary to lack of IOP control, visual ﬁeld or ocular 
imaging worsening, lack of tolerance, then weak compliance. Observed rates of very 
satisﬁed patients between BB group and PG are as follows: 37.2% CI95 [29.4; 45.8] 
vs. 28.9% CI95 [23.6; 34.9], rates of very compliant patients: 65.9% CI95 [57.4; 
73.5] vs. 61% IC95 [54.7; 66.9]. CONCLUSIONS: This study demonstrated the large 
part of medical treatment in OAG/OHT. Among them PG are mostly prescribed in 
monotherapy or ﬁxed association with a high level of satisfaction and compliance 
according physicians.
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OBJECTIVES: Psoriasis is a chronic skin disorder affecting 1,5–3% of population and 
its cost to the society has been estimated between $600 and $900/patient/year. Pre-
scription compliance, adherence to an appropriate follow-up program, and changes 
in patients everyday lives represent an essential approach to reach and maintain clini-
cal remission. Our study wants to measure psoriasis related self-efﬁcacy through a 
questionnaire speciﬁcally developed for this purpose (Psoriasis Empowerment Enquiry 
in the Routinely practice or PEER). METHODS: The study was an observational, 
cross-sectional survey. 240 consecutive psoriatic outpatients were asked to ﬁll the 
questionnaire. The PEER is a 20-item Likert-type questionnaire and generates an 
overall empowerment score obtained by summing individual items; since we have 
deﬁned empowerment as mastering the knowledge about psoriasis, learning from past 
experiences and owning skills to combine both to comply with recommendations of 
physicians, the PEER was conceived with 3 subscales. RESULTS: A total of 223 
respondents were analyzed. Psoriatic patients more than 44 years old reported higher 
values in the overall score (p  0.01) and in the skills subscale score (p  0.03) while 
educational level didn’t affect it. People suffering from psoriasis from more than one 
year had a higher overall (p  0.005) and knowledge subscale (p  0.001) scores but 
no signiﬁcant score differences were recorded comparing the number of consultations; 
psoriatic arthritis cases reported higher scores (p  0.001) than those affected by others 
psoriasis subtype. CONCLUSIONS: patients older than age 44, arthropathic patients 
or cases affected from more than one year reported higher scores reﬂecting a higher 
level of empowerment; psoriatic patients are in great need for self-management of their 
chronic disease. We introduce a questionnaire to survey empowerment among psoria-
tic patients that could represent a useful tool to evaluate the efﬁcacy of any kind of 
interventions in this disabling skin disorder.
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OBJECTIVES: This study was conducted to examine the face and content validity as 
well as psychometric properties of the Eyelash Satisfaction Questionnaire (ESQ) 
among cancer patients. Additionally, the aim was to determine whether the measure-
ment properties were equivalent across non-cancer and cancer patients. METHODS: 
Two focus groups (n  15) were conducted among cancer patients post-chemotherapy 
to examine the validity of the conceptual framework and test the face and content 
validity of the ESQ. A web survey was conducted among adults with cancer. Classical 
Test Theory (CTT) and latent variable modeling techniques were performed using data 
collected from the web survey. Conﬁrmatory Factor Analysis (CFA), Multiple Group 
Structural Equation Modeling (MG-SEM), and Differential Item Functioning (DIF) 
were performed to examine the accuracy and stability of the three domains between 
non-cancer (n  909) and post-chemotherapy cancer samples (n  595) in the US. 
RESULTS: Qualitative analysis of the focus group discussions indicated that the con-
ceptual framework established for cancer patients was similar to that for non-cancer 
patients. Additionally, support was found for the face and content validity of the ESQ. 
Internal consistency was found to be high across all three domains (Cronbach’s 
A  0.93, .90, 0.80) and item-to-domain correlations were high (.55–.84). The factor 
structure of the original survey ﬁt the cancer data well with factor loadings ranging 
from .64 to 93. Measurement invariance models provided good ﬁt to the data 
(NNFI  0.97, RMSEA  0.04). Signiﬁcant DIF was found between the two samples 
on two items but the effect sizes of the differences were small (Cohen’s d’s  0.10) 
and substantively negligible. CONCLUSIONS: The research ﬁndings indicate good 
overall performance of the ESQ among cancer patients providing support for its use 
in this population. Additionally, the measurement properties between non-cancer and 
cancer patients were found to be equivalent.
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OBJECTIVES: It is important that a questionnaire can detect impact on HRQoL when 
the disease is ‘active’ and when is not active in patients with Psoriasis. We have 
developed a new questionnaire where the items have been created to evaluate the 
impact of the disease in different phases. METHODS: In order to deﬁne the main 
dimensions, a literature review and a F.G with 5 dermatologists were performed. A 
semi-structured interview was conducted with 20 patients (10 with active and 10 with 
non active). From the content of the interviews several items were identiﬁed. Each 
item was subsequently rated by the dermatologist. The items were administered to a 
sample of 171 patients (52.1% active and 47.9% non active). A factor analysis and 
a Rasch analysis were performed to obtain the ﬁnal pilot questionnaire before the 
validation study. RESULTS: After qualitative reduction, a 37 items questionnaire was 
obtained (score 0; poor HRQoL to 100; good HRQol) (PSO-LIFE 37). Factor analysis 
identiﬁed 6 dimensions (variance explained of 72.4%). Rasch analysis was used to 
exclude those items with INFIT or OUTFIT  1.30 and 0.70 or redundant with other 
items. This ﬁnal questionnaire (PSO-LIFE 20) has good internal consistency (Cron-
bach’s alpha  0.94). Comparative psychometric performance between PSO-LIFE 37 
and PSO-LIFE 20 showed similar internal consistency (0.97 and 0.94), and item cor-
relation-overall score (0.34–0.82 and 0.35–0.81). PSO-LIFE 20 showed differences 
(p  0.042) with severity of psoriasis and between patients with active and non active 
disease (p  0.01) (high score in patients with mild severity, and in patients with non 
active, which reﬂect good HRQoL). CONCLUSIONS: PSO-LIFE is a new question-
naire of 20 items, with a priori good psychometric properties though validation is 
needed through a formal validation process in a sample of adequate size. Preliminary 
results show that highest impact on HRQoL is observed in patients with active 
disease.
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BACKGROUND: The number of patients with atopic dermatitis is increasing., AD 
in industrialized countries concerns 5 to 20 % of children between 6&7 years old, of 
which nearly 10% still suffer from this disease during adulthood. Consequently; atopic 
dermatitis has become a true public health concern with namely difﬁculties in diag-
nosis and patient’s management. OBJECTIVES: In order to rapidly and effectively 
refer patients with AD to dermatologists or paediatricians, our work has aimed at 
designing and validating a questionnaire of presumed diagnosis of AD METHODS: 
This questionnaire was designed and based on a large review of international scientiﬁc 
literature, in particular from articles about diagnosis criteria by Haniﬁ and Rajka and 
the UK Working Party, interviews of experts and a series of structured interviews of 
patients with AD of different levels of severity, hence forming a rich and structured 
verbatim. RESULTS: A questionnaire, using simple vocabulary, and comprising 20 
questions, has been designed. Answers to each question are dichotomic; the subject 
answering either « yes » or « no », so as to prevent any confusion. During test phase, 
it was found necessary to add « do not know »as a possible answer. 8 questions focus 
on the medical history of the patient and his/her family (parents and brothers/sisters), 
2 questions dealt with difﬁculties in getting to sleep as well as the quality of sleep, 9 
